Revolution Medicines(RVMD.US)

Last Updated 19:00:00 ET
longbridge loading

GraniteShares Files High-Octane 2X ETFs Tied To Nuclear, AI, Biotech Momentum Stocks

benzinga_article·
US
XE
+4.57%
US
MAIR
+0.55%
US
RVMD
+2.03%
benzinga_article·
US
XE
+4.57%
US
MAIR
+0.55%
US
RVMD
+2.03%

Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report

benzinga_article·
US
RVMD
+2.03%
US
PBE
+0.11%
US
FBT
+0.54%
benzinga_article·
US
RVMD
+2.03%
US
PBE
+0.11%
US
FBT
+0.54%

US Cancer Clinics Rush to Access Revolutionary Pancreatic Cancer Drug Daraxonrasib

Stock Invest·
US
RVMD
+2.03%
US
LABU
-2.35%
US
XBI
-0.69%
Stock Invest·
US
RVMD
+2.03%
US
LABU
-2.35%
US
XBI
-0.69%

$100 Invested In Revolution Medicines 5 Years Ago Would Be Worth This Much Today

benzinga_article·
US
RVMD
+2.03%
US
LABU
-2.35%
US
XBI
-0.69%
benzinga_article·
US
RVMD
+2.03%
US
LABU
-2.35%
US
XBI
-0.69%

LifeSci Capital Sticks to Their Buy Rating for Revolution Medicines (RVMD)

Tip Ranks·
US
RVMD
+2.03%
US
XBI
-0.69%
US
IBB
+0.10%
Tip Ranks·
US
RVMD
+2.03%
US
XBI
-0.69%
US
IBB
+0.10%

Revolution Medicines Warrants: Balancing Dilution Risk and Potential Worthlessness Ahead of 2026 Expiry

Tip Ranks·
US
RVMD
+2.03%
US
BIB
+0.05%
US
FBT
+0.54%
Tip Ranks·
US
RVMD
+2.03%
US
BIB
+0.05%
US
FBT
+0.54%

Evercore ISI Sticks to Their Buy Rating for Revolution Medicines (RVMD)

Tip Ranks·
US
RVMD
+2.03%
US
XBI
-0.69%
US
SBIO
-1.24%
Tip Ranks·
US
RVMD
+2.03%
US
XBI
-0.69%
US
SBIO
-1.24%

Revolution Medicines: Buy Rating Backed by Strong Daraxon Launch Signals and Pancreatic Cancer Upside Optionality

Tip Ranks·
US
RVMD
+2.03%
US
XBI
-0.69%
US
SBIO
-1.24%
Tip Ranks·
US
RVMD
+2.03%
US
XBI
-0.69%
US
SBIO
-1.24%
© 2026 Longbridge｜Disclaimer